4-Hydroxynonenal impairs miRNA maturation in heart failure via Dicer post-translational modification
Background and Aims
Developing novel therapies to battle the global public health burden of heart failure remains challenging. This study investigates the underlying mechanisms and potential treatment for 4-hydroxynonenal (4-HNE) deleterious effects in heart failure.
Methods
Biochemical, functional, and histochemical measurements were applied to identify 4-HNE adducts in rat and human failing hearts. In vitro studies were performed to validate 4-HNE targets.
Results
4-HNE, a reactive aldehyde by-product of mitochondrial dysfunction in heart failure, covalently inhibits Dicer, an RNase III endonuclease essential for microRNA (miRNA) biogenesis. 4-HNE inhibition of Dicer impairs miRNA processing. Mechanistically, 4-HNE binds to recombinant human Dicer through an intermolecular interaction that disrupts both activity and stability of Dicer in a concentration- and time-dependent manner. Dithiothreitol neutralization of 4-HNE or replacing 4-HNE-targeted residues in Dicer prevents 4-HNE inhibition of Dicer in vitro. Interestingly, end-stage human failing hearts from three different heart failure aetiologies display defective 4-HNE clearance, decreased Dicer activity, and miRNA biogenesis impairment. Notably, boosting 4-HNE clearance through pharmacological re-activation of mitochondrial aldehyde dehydrogenase 2 (ALDH2) using Alda-1 or its improved orally bioavailable derivative AD-9308 restores Dicer activity. ALDH2 is a major enzyme responsible for 4-HNE removal. Importantly, this response is accompanied by improved miRNA maturation and cardiac function/remodelling in a pre-clinical model of heart failure.
Conclusions
4-HNE inhibition of Dicer directly impairs miRNA biogenesis in heart failure. Strikingly, decreasing cardiac 4-HNE levels through pharmacological ALDH2 activation is sufficient to re-establish Dicer activity and miRNA biogenesis; thereby representing potential treatment for patients with heart failure.
Top-30
Journals
|
1
2
|
|
|
European Heart Journal
2 publications, 16.67%
|
|
|
Current Opinion in Endocrine and Metabolic Research
1 publication, 8.33%
|
|
|
Medicinal Chemistry Research
1 publication, 8.33%
|
|
|
Journal of Physiology
1 publication, 8.33%
|
|
|
Military Medical Research
1 publication, 8.33%
|
|
|
Circulation
1 publication, 8.33%
|
|
|
Advanced Materials
1 publication, 8.33%
|
|
|
Biochemical Pharmacology
1 publication, 8.33%
|
|
|
International Journal of Molecular Sciences
1 publication, 8.33%
|
|
|
Mediators of Inflammation
1 publication, 8.33%
|
|
|
1
2
|
Publishers
|
1
2
|
|
|
Oxford University Press
2 publications, 16.67%
|
|
|
Elsevier
2 publications, 16.67%
|
|
|
Springer Nature
2 publications, 16.67%
|
|
|
Wiley
2 publications, 16.67%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 8.33%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 8.33%
|
|
|
MDPI
1 publication, 8.33%
|
|
|
Hindawi Limited
1 publication, 8.33%
|
|
|
1
2
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.